Gastrinoma

• Gastrinoma is a rare neuroendocrine tumor primarily found in the pancreas or duodenum.
• It leads to Zollinger-Ellison syndrome (ZES) due to excessive gastrin production and stomach acid.
• Common symptoms include severe abdominal pain, chronic diarrhea, and heartburn.
• Diagnosis involves blood tests for gastrin levels and various imaging techniques.
• Treatment focuses on managing acid secretion and surgically removing the tumor when possible.

What is Gastrinoma?

Gastrinoma refers to a rare neuroendocrine tumor that originates from gastrin-producing cells, most commonly located in the pancreas or the upper part of the small intestine (duodenum). These tumors secrete abnormally high levels of gastrin, a hormone that stimulates the stomach to produce hydrochloric acid. The excessive acid production is the hallmark of Zollinger-Ellison syndrome (ZES), a condition primarily caused by gastrinomas.

While gastrinomas are rare, they can be benign or malignant, with a significant percentage having the potential to metastasize, often to the liver or lymph nodes. The incidence of gastrinoma is estimated to be around 0.5 to 2 cases per million people annually, making it a relatively uncommon diagnosis. (Source: National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK).

Gastrinoma Symptoms and Diagnosis

The symptoms associated with gastrinoma are primarily due to the severe peptic ulcer disease and acid-related complications caused by the excessive gastrin. Common gastrinoma symptoms include persistent and often severe abdominal pain, chronic diarrhea that can be greasy or watery, heartburn, nausea, vomiting, and unintended weight loss. In some cases, patients may experience gastrointestinal bleeding, which can manifest as black, tarry stools (melena) or vomiting blood (hematemesis).

The gastrinoma diagnosis process typically begins with a thorough medical history and physical examination, followed by specific laboratory and imaging tests. Key diagnostic steps include:

• Fasting Serum Gastrin Levels: Elevated gastrin levels in the blood are a primary indicator.
• Secretin Stimulation Test: This test helps differentiate gastrinomas from other causes of high gastrin by observing the gastrin response to secretin injection.
• Endoscopic Ultrasound (EUS): Provides detailed images of the pancreas and duodenum, helping to locate small tumors.
• Cross-sectional Imaging: Computed tomography (CT) scans or magnetic resonance imaging (MRI) of the abdomen are used to identify tumors and assess for metastasis.
• Somatostatin Receptor Scintigraphy (SRS): Also known as an Octreoscan, this nuclear medicine scan helps locate gastrinomas and their metastases, as these tumors often express somatostatin receptors.

Causes and Treatment Options for Gastrinoma

The exact causes of gastrinoma are not fully understood in all cases. Approximately 75-80% of gastrinomas occur sporadically, meaning they arise without a clear inherited predisposition. However, about 20-25% of gastrinomas are associated with Multiple Endocrine Neoplasia type 1 (MEN1) syndrome, a genetic disorder characterized by tumors in multiple endocrine glands, including the parathyroid glands, pituitary gland, and pancreas. Individuals with MEN1 syndrome inherit a mutation in the MEN1 gene, which increases their risk of developing gastrinomas and other endocrine tumors.

Gastrinoma treatment options aim to control acid secretion and, when possible, remove the tumor. Medical management is crucial for symptom relief and preventing complications. Proton pump inhibitors (PPIs) are highly effective medications used to significantly reduce stomach acid production. For localized tumors, surgical resection is often the preferred approach, offering the potential for a cure, especially if the tumor is small and has not spread. For larger or metastatic tumors, surgery may involve debulking to reduce tumor burden and alleviate symptoms.

Beyond surgery, other therapies may be considered, particularly for metastatic or unresectable tumors. These can include somatostatin analogs (e.g., octreotide, lanreotide) to control hormone secretion and tumor growth, chemotherapy, targeted therapies, or liver-directed therapies such as radiofrequency ablation or embolization for liver metastases. A multidisciplinary team approach, involving endocrinologists, gastroenterologists, surgeons, and oncologists, is essential for optimal patient care and management of this complex condition.